Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer

被引：7
|
作者：
Huang, Linjuan [1 ,2 ,3 ,4 ]
Zhang, Jing [1 ,2 ,3 ,4 ]
Deng, Youling [1 ,2 ,3 ,4 ]
Wang, Hao [4 ,5 ,6 ]
Zhao, Piao [1 ,2 ,3 ,4 ]
Zhao, Guozhi [1 ,2 ,3 ,4 ]
Zeng, Wei [4 ,7 ]
Wang, Yonghui [4 ,8 ]
Chen, Connie [4 ]
Wagstaff, William [4 ]
Haydon, Rex C. [4 ]
Reid, Russell R. [4 ,9 ]
He, Tong-Chuan [4 ,10 ]
Shen, Le [4 ,10 ]
Luu, Hue H. [4 ]
Zhao, Ling [1 ,2 ,3 ,4 ]
机构：
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing 400046, Peoples R China
[2] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400046, Peoples R China
[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing 400046, Peoples R China
[4] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA
[5] Chongqing Med Univ, Minist Educ, Sch Lab Med, Key Lab Diagnost Med, Chongqing 400016, Peoples R China
[6] Chongqing Med Univ, Sch Lab Med, Chongqing 400016, Peoples R China
[7] Jianghan Univ, Affiliated Hosp 2, Dept Neurol, Wuhan 430050, Hubei, Peoples R China
[8] Shanghai Jiao Tong Univ, Sch Med, Dept Clin Lab Med, Shanghai 200000, Peoples R China
[9] Univ Chicago, Med Ctr, Dept Surg Sect Plast Surg, Lab Craniofacial Suture Biol & Dev, Chicago, IL 60637 USA
[10] Univ Chicago, Med Ctr, Dept Surg, Chicago, IL 60637 USA
来源：
GENES & DISEASES | 2023年 / 10卷 / 04期
基金：
美国国家卫生研究院;
关键词：
Chemotherapy resistance; Cisplatin; Drug repurposing; Niclosamide; Ovarian cancer; MESENCHYMAL STEM-CELLS; BMP9-INDUCED OSTEOGENIC DIFFERENTIATION; SUPPRESSES TUMOR-GROWTH; WNT/BETA-CATENIN; ANTIHELMINTHIC NICLOSAMIDE; OSTEOBLAST DIFFERENTIATION; GENE-EXPRESSION; INHIBITION; PATHWAY; PROLIFERATION;
D O I：
10.1016/j.gendis.2022.12.005
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Ovarian cancer (OC) is one of the most lethal malignancies of the female reproduc-tive system. OC patients are usually diagnosed at advanced stages due to the lack of early diag-nosis. The standard treatment for OC includes a combination of debulking surgery and platinum-taxane chemotherapy, while several targeted therapies have recently been approved for maintenance treatment. The vast majority of OC patients relapse with chemoresistant tu-mors after an initial response. Thus, there is an unmet clinical need to develop new therapeu-tic agents to overcome the chemoresistance of OC. The anti-parasite agent niclosamide (NA) has been repurposed as an anti-cancer agent and exerts potent anti-cancer activities in human cancers including OC. Here, we investigated whether NA could be repurposed as a therapeutic
引用
收藏
页码：1687 / 1701
页数：15
相关论文
共 50 条
  • [21] Targeting NPEPPS overcomes cisplatin resistance in patientderived bladder cancer tumoroids
    Scholtes, Mathijs P.
    Akbarzadeh, Maryam
    Romal, Shahla
    van Dijk, Miranda
    Kan, Tsung Wai
    Mahmoudi, Tokameh
    Zuiverloon, Tahlita C.
    CANCER RESEARCH, 2023, 83 (07)
  • [22] Metformin overcomes cisplatin-resistance in triple negative breast cancer
    Lau, Ying Ka Ingar
    Shaw, Jacquelyn M.
    Campbell, Julie L.
    Maurer, Matthew A.
    CANCER RESEARCH, 2011, 71
  • [23] Napabucasin overcomes cisplatin resistance in ovarian germ cell tumor-derived cell line by inhibiting cancer stemness
    Silvia Schmidtova
    Lambert C. J. Dorssers
    Katarina Kalavska
    Ad J. M. Gillis
    J. Wolter Oosterhuis
    Hans Stoop
    Svetlana Miklikova
    Zuzana Kozovska
    Monika Burikova
    Katarina Gercakova
    Erika Durinikova
    Michal Chovanec
    Michal Mego
    Lucia Kucerova
    Leendert H. J. Looijenga
    Cancer Cell International, 20
  • [24] Napabucasin overcomes cisplatin resistance in ovarian germ cell tumor-derived cell line by inhibiting cancer stemness
    Schmidtova, Silvia
    Dorssers, Lambert C. J.
    Kalavska, Katarina
    Gillis, Ad J. M.
    Oosterhuis, J. Wolter
    Stoop, Hans
    Miklikova, Svetlana
    Kozovska, Zuzana
    Burikova, Monika
    Gercakova, Katarina
    Durinikova, Erika
    Chovanec, Michal
    Mego, Michal
    Kucerova, Lucia
    Looijenga, Leendert H. J.
    CANCER CELL INTERNATIONAL, 2020, 20 (01)
  • [25] METALLOTHIONEIN GENE-EXPRESSION AND RESISTANCE TO CISPLATIN IN HUMAN OVARIAN-CANCER
    SCHILDER, RJ
    HALL, L
    MONKS, A
    HANDEL, LM
    FORNACE, AJ
    OZOLS, RF
    FOJO, AT
    HAMILTON, TC
    INTERNATIONAL JOURNAL OF CANCER, 1990, 45 (03) : 416 - 422
  • [26] Targeting LIFR overcomes HDAC inhibitor resistance in ovarian cancer
    Li, Mengxing
    Viswanadhapalli, Suryavathi
    Sareddy, Gangadhara Reddy
    Santhamma, Bindu
    Yan, Hui
    Xu, Zhenming
    Kost, Edward
    Tekmal, Rajeshwar Rao
    Nair, Hareesh B.
    Nickisch, Klaus J.
    Vadlamudi, Ratna K.
    CANCER RESEARCH, 2019, 79 (13)
  • [27] Experimental study on the mechanism of cisplatin resistance and its reversion in human ovarian cancer
    Liang, ZD
    Bian, DH
    CHINESE MEDICAL JOURNAL, 1996, 109 (05) : 353 - 355
  • [28] Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer
    Brown, Dawn P. G.
    Chin-Sinex, Helen
    Nie, Bei
    Mendonca, Marc S.
    Wang, Mu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (04) : 723 - 730
  • [29] ENHANCED DNA-REPAIR AND RESISTANCE TO CISPLATIN IN HUMAN OVARIAN-CANCER
    LAI, GM
    OZOLS, RF
    SMYTH, JF
    YOUNG, RC
    HAMILTON, TC
    BIOCHEMICAL PHARMACOLOGY, 1988, 37 (24) : 4597 - 4600
  • [30] Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer
    Dawn P. G. Brown
    Helen Chin-Sinex
    Bei Nie
    Marc S. Mendonca
    Mu Wang
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 723 - 730
12345